United States Market for Ankylosing Spondylitis Pharmacotherapy

Introduction

This research service covers the United States market for ankylosing spondylitis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies; background standard of care therapies are not covered in this study. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors and non-TNF biologics.

Table of Contents

1. Ankylosing Spondylitis Pharmacotherapeutics Market

• Executive Summary and Market Overview

2. Ankylosing Spondylitis Pharmacotherapeutics Market - Total Ankylosing Spondylitis Pharmacotherapeutics Market

• Drivers and Restraints
• Forecasts and Trends
• Demand Analysis
• Market Share and Competitive Analysis

3. TNF Inhibitor Segment

• Segment Breakdown and Market Engineering Measurements
• Patient Forecast
• Pricing Trends and Forecast
• Revenue Forecast
• Market Share Analysis

4. Non-TNF Biologics Segment

• Segment Breakdown
• Patient Forecast
• Pricing Trends and Forecast
• Revenue Forecast

5. The Last Word

• Summary and Conclusions

6. Appendix

• Appendix

United States Market for Ankylosing Spondylitis Pharmacotherapy published by Frost & Sullivan in July 5, 2012. This report consists of 85 Pages and the price starts from US $ 6000.